Combining angiogenic gene and stem cell therapies for myocardial infarction

Journal of Gene Medicine

Volumn 11, Issue 9, 2009, Pages 743-753

  Pons, Jennifer ^a   Huang, Yu ^b   Takagawa, Junya ^a,c   Arakawa Hoyt, Janice ^b   Ye, Jianqin ^a   Grossman, William ^a   Kan, Yuet Wai ^a,b   Su, Hua ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Imizu City Hospital   (Japan)

^d NONE   (United States)

Author keywords

Adeno associated viral vector; Mesenchymal stem cells; Myocardial infarction; Stem cell therapy; Vascular endothelial growth factor

Indexed keywords

GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC GENE THERAPY; ARTICLE; CELL HOMING; CELL ISOLATION; CELL SURVIVAL; ECHOCARDIOGRAPHY; ENGRAFTMENT; FEMALE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL SEPARATION; DNA PRIMERS; FEMALE; GENE THERAPY; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MIRIDAE; MUS MUSCULUS;

EID: 70349506739     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1362     Document Type: Article

References (43)

1. Mack CA, Patel SR, Schwarz EA, et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 1998; 115: 168-176.
2. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2: 534-539.
3. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-18.
4. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-98.
5. Menasche P. Challenging the cardiac differentiation of bone marrow cells: a clinical perspective. Mol Ther 2008; 16: 1000-1001.
6. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-1201.
7. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-368.
8. Noiseux N, Gnecchi M, Lopez-Ilasaca M, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006; 14: 840-850.
9. Su H, Lu R, Kan YW. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA 2000; 97: 13801-1386.
10. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
11. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Hum Gene Ther 1997; 8: 215-27.
12. Luo Z, Diaco M, Murohara T, Ferrara N, Isner JM, Symes JF. Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. Ann Thorac Surg 1997; 64: 993-998.
13. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factorinduced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-2634.
14. Pons J, Huang Y, Arakawa-Hoyt J, et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts. Biochem Biophys Res Commun 2008; 376: 419-422.
15. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102: 898-901.
16. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998; 2: 549-558.
17. Su H, Arakawa-Hoyt J, Kan YW. Adeno-associated viral vectormediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc Natl Acad Sci USA 2002; 99: 9480-9485.
18. Su H, Joho S, Huang Y, et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci USA 2004; 101: 16280-16285.
19. Matsushita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 1998; 5: 938-945.
20. Muller-Ehmsen J, Whittaker P, Kloner RA, et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol 2002; 34: 107-116.
21. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005; 46: 1339-1350.
22. Chapdelaine P, Vignola K, Fortier MA. Protein estimation directly from SDS-PAGE loading buffer for standardization of samples from cell lysates or tissue homogenates before western blot analysis. Biotechniques 2001; 31: 478-482.
23. Ishizaka S, Sievers RE, Zhu BQ, et al. New technique for measurement of left ventricular pressure in conscious mice. Am J Physiol Heart Circ Physiol 2004; 286: H1208-H1215.
24. Wieczorek G, Steinhoff C, Schulz R, et al. Gene expression profile of mouse bone marrow stromal cells determined by cDNA microarray analysis. Cell Tissue Res 2003; 311: 227-237.
25. Su H, Huang Y, Takagawa J, et al. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther 2006; 13: 1495-1502.
26. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 2001; 33: 907-921.
27. Li RK, Mickle DA, Weisel RD, et al. Natural history of fetal rat cardiomyocytes transplanted into adult rat myocardial scar tissue. Circulation 1997; 96: II179-II186.
28. Davani S, Marandin A, Mersin N, et al. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 2003; 108(Suppl 1): II253-II258.
29. Liu X, Chen Y, Zhang F, et al. Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium. Scand Cardiovasc J 2007; 41: 95-101.
30. Martin JC, Avant RF, BowmanMA, et al. The Future of Family Medicine: a collaborative project of the family medicine community. Ann Fam Med 2004; 2(Suppl 1): S3-S32.
31. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004; 94: 678-685.
32. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004; 109: 1543-1549.
33. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929-933.
34. Reinlib L, Field L. Cell transplantation as future therapy for cardiovascular disease? A workshop of the National Heart, Lung, and Blood Institute. Circulation 2000; 101: E182-E187.
35. Miyagawa S, Sawa Y, Taketani S, et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation, 2002; 105: 2556-2561.
36. Duan HF, Wu CT, Wu DL, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 2003; 8: 467-474.
37. Suzuki K, Murtuza B, Smolenski RT, et al. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001; 104: 1207-1212.
38. Hattan N, Warltier D, Gu W, et al. Autologous vascular smooth muscle cell-based myocardial gene therapy to induce coronary collateral growth. Am J Physiol Heart Circ Physiol 2004; 287: H488-H493.
39. Retuerto MA, Schalch P, Patejunas G, et al. Angiogenic pretreatment improves the efficacy of cellular cardiomyoplasty performed with fetal cardiomyocyte implantation. J Thorac Cardiovasc Surg 2004; 127: 1041-1049.
40. Sakakibara Y, Nishimura K, Tambara K, et al. Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J Thorac Cardiovasc Surg 2002; 124: 50-56.
41. Du L, Kido M, Lee DV, et al. Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther 2004; 10: 604-608.
42. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53.
43. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol 2005; 23: 321-328.